Symbiotec Pharmalab IPO Allotment Status: Check Online via MUFG Intime, BSE & NSE

Symbiotec Pharmalab IPO Allotment Status – Updated 21 August 2026: Anchor bidding opens today, 21 August 2026, ahead of the public issue, which opens Monday, 24 August 2026, and closes Thursday, 27 August 2026. Allotment is expected to be finalised the very next working day, Friday, 28 August 2026. This guide explains when allotment should be visible, where to check it, and what happens after allotment.

Key Takeaways

• Allotment date: expected to be finalised on 28 August 2026, one working day after bidding closes on 27 August 2026.
• Registrar: MUFG Intime India Pvt. Ltd. – check status there first, or via BSE/NSE.
• Listing date: tentatively set for 1 September 2026 on both BSE and NSE.
• Price band and lot size: ₹938–₹988 per share, in lots of 15 shares.
• Use of proceeds: the ₹1,607 crore offer-for-sale – more than ten times the size of the fresh issue – goes to the promoter entity and two existing investors, not the company; the ₹150 crore fresh issue is earmarked mostly for debt repayment.

Symbiotec Pharmalab IPO: Key Details at a Glance

What Is the Symbiotec Pharmalab IPO Timeline?

When Will Symbiotec Pharmalab IPO Allotment Be Out?

IPO allotment in India follows a fixed regulatory timeline. The registrar finalises the basis of allotment on T+1 – one working day after the issue closes. For Symbiotec Pharmalab, with bidding closing on Thursday, 27 August, allotment is expected to be finalised the next working day, Friday, 28 August 2026. Refunds and demat credit should follow by 31 August, once the 29–30 August weekend has passed, with listing tentatively set for 1 September 2026 on both BSE and NSE.

How to Check Symbiotec Pharmalab IPO Allotment Status

Method 1: Via MUFG Intime (Registrar)

MUFG Intime is the official registrar for this IPO and the fastest source for allotment data, since it manages the process directly.

• Visit the MUFG Intime IPO allotment status page.
• Select “Symbiotec Pharmalab Limited” from the company dropdown.
• Choose your verification method – PAN, Application Number, or DP/Client ID.
• Enter the details and submit to view your allotment status.

Method 2: Via BSE

• Visit the BSE Application Status Check page.
• Select “Symbiotec Pharmalab Limited” as the issue name.
• Enter your Application Number and PAN.
• Submit to view your status. Data stays available on BSE for about a week after issue closure.

Method 3: Via NSE

• Visit NSE’s bid verification page.
• Complete one-time registration with your PAN if you haven’t already.
• Select “Symbiotec Pharmalab Limited” and view your application status.

How Is the Basis of Allotment Decided?

The basis of allotment follows SEBI’s standard framework and is the same across mainboard IPOs, including Symbiotec Pharmalab. In the retail category, if the issue is oversubscribed, allotment is done through a computerised lottery (draw of lots), so each successful applicant gets at least one full lot rather than a partial allocation. In the NII and QIB categories, allotment is proportionate to the shares bid for, subject to the rounding rules the registrar applies when a category is oversubscribed.

What Happens If You’re Not Allotted Shares?

If you don’t receive an allotment, the amount blocked through ASBA is unblocked automatically, and refunds for other application modes are processed by 31 August 2026. You’ll also get an email/SMS update from the registrar and your depository.

What Will Symbiotec Pharmalab Do With the IPO Proceeds?

Of the ₹150 crore fresh issue, ₹112.50 crore is earmarked for prepaying or repaying certain outstanding company borrowings, with the remainder set aside for general corporate purposes. The separate ₹1,607 crore offer-for-sale – over ten times the size of the fresh issue – is the sale of existing shares by promoter entity Satwani Holdings LLP together with financial investors Rosewood Investments and India Business Excellence Fund III. That money goes to the selling shareholders personally, not to the company.

Who Is Symbiotec Pharmalab Limited?

Symbiotec Pharmalab Limited, incorporated in 2002 and headquartered in Indore, Madhya Pradesh, is a global active pharmaceutical ingredient (API) manufacturer with a leading position in corticosteroid and steroidal-hormone APIs, alongside nutritional and speciality ingredients. It runs two manufacturing facilities with a combined chemical synthesis capacity of about 584.67 metric tonnes and fermentation capacity of 300 kilolitres, exporting to regulated and emerging markets. For FY26, the company reported revenue of ₹872.26 crore (up around 15% year-on-year) and profit after tax of ₹109.90 crore, with an EBITDA margin of roughly 26.6%. The company’s promoters are Anil Satwani, Kashish Satwani, and Sushil Satwani, together with promoter entity Satwani Holdings LLP, who collectively held about 34.47% of the company before the IPO. Existing institutional investors Rosewood Investments and India Business Excellence Fund III are also selling part of their stake through the offer for sale.

Related Reading on Share.Market

Symbiotec Pharmalab is one of several IPOs currently open or upcoming. Track live and upcoming mainboard and SME IPOs on the Share.Market IPO page, and read our related guides on how to check IPO allotment status, how to invest in an IPO, and how many lots to apply for to improve your chances of allotment.

Don’t want to miss the next IPO? Open a free demat account on Share.Market in minutes and apply the moment bidding opens.

FAQs